Search Results - I. Flinn

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES by A. Mato, A. Danilov, M. R. Patel, M. Tees, I. Flinn, W. Ai, K. Patel, M. Wang, S. M. O’Brien, S. Nandakumar, M. Tan, E. Meredith, M. Gessner, S. Y. Kim, A. Wiestner, W. G. Wierda

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by M. Dickinson, M. Kwon, J. Briones, U. Jäger, K. Kato, E. Bachy, D. Blaise, N. Boissel, N. Shah, M Frigault, P. Riedell, L. Shune, T. Teshima, X. Zhu, E. Orlando, L. Yi, J. Davis, E. Bleickardt, I. Flinn, P. Barba, P. Barba

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY by M. Trněný, L. Fogliatto, F. Gardner, I. Flinn, J.-F. Larouche, C. Haioun, M. Canales, H. Goto, R. Hajek, G. Salles, J. Qiu, A. Campinha-Bacote, M. Yan, R. Kothari, G. Man, D. Sahin, J. Hirata, C. Lee, H. Tilly, C. Flowers

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by A. R. Mato, J. M. Pagel, C. C. Coombs, N. N. Shah, N. Lamanna, T. Munir, E. Lech-Maranda, T. A. Eyre, J. A. Woyach, W. G. Wierda, C. Y. Cheah, J. B. Cohen, L. E. Roeker, M. R. Patel, B. Fakhri, M. A. Barve, C. Tam, D. Lewis, J. N. Gerson, A. J. Alencar, C. Ujjani, I. Flinn, S. Sundaram, S. Ma, D. Jagadeesh, J. Rhodes, J. Taylor, O. Abdel-Wahab, P. Ghia, S. J. Schuster, D. Wang, B. Nair, E. Zhu, D. E. Tsai, M. S. Davids, J. R. Brown, W. Jurczak

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by T. A. Eyre, M. L. Wang, N. N. Shah, A. J. Alencar, J. N. Gerson, M. R. Patel, B. Fakhri, E. Vandenberghe, W. Jurczak, X. N. Tan, K. L. Lewis, T. Fenske, Y. Wang, C. C. Coombs, I. Flinn, D. Lewis, S. Le Gouill, M. Gandhi, C. Chay, M. L. Palomba, J. A. Woyach, J. M. Pagel, N. Lamanna, J. P. Sharman, D. J. Andorsky, J. B. Cohen, M. A. Barve, P. Ghia, M. Yin, P. L. Zinzani, C. Ujjani, Y. Koh, K. Izutsu, E. Lech-Maranda, J. Kherani, C. Tam, S. Sundaram, B. Nair, D. E. Tsai, M. Balbas, A. R. Mato, C. Y. Cheah

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: